Cargando…

Profile of secukinumab in the treatment of psoriasis: current perspectives

Secukinumab (Cosentyx™) is a human monoclonal IgG1k antibody that has been developed to target and block the actions of IL-17A. It is known that this cytokine is elevated in lesions of psoriasis. Interleukins in the Th17 pathway play a pivotal role in the pathogenesis of psoriasis and have thus beco...

Descripción completa

Detalles Bibliográficos
Autores principales: Roman, Michael, Madkan, Vandana K, Chiu, Melvin W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671779/
https://www.ncbi.nlm.nih.gov/pubmed/26664127
http://dx.doi.org/10.2147/TCRM.S79053